Sam Moqadam on Unsplash
News Article
The European Commission approved the use of Biomarin’s treatment for achondroplasia, one of the most common forms of dwarfism.
Value-Based Healthcare: Industry Endgame
Analysis
Moving the focus of healthcare from sickness treatment to sustained health demands disruption and structural change.
Non-COVID-19 Treatments, How Are They Progressing?
News Article
In healthcare, time is gold. How much longer can patients wait for treatments due to COVID-19?
Pharma Opinions on the “Payment By Results” Model
Analysis
Pharmaceutical industry leaders share their views on the “payment by results” method to increase healthcare access.
IGSA Medical
Spotlight
Timely and comprehensive patient care is the central axis for improving quality of life.
David Lopez
View from the Top
David López
Country Manager
BioMarin Pharmaceuticals
BioMarin Pharmaceuticals is a biotechnology company developing and commercializing innovative biopharmaceuticals for rare genetic diseases.
David Lopez
Insight
David Lopez
Country Manager
BioMarin Mexico
Rare diseases are often difficult to treat because developing medications for them is costly for manufacturers
Subscribe to BioMarin